MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

Robert Z Orlowski, Thierry Facon, Shaji K. Kumar, Torben Plesner, Philippe Moreau, Nizar J Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent FrenzelXavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z Usmani

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

OriginalsprogEngelsk
ArtikelnummerS252
TidsskriftClinical Lymphoma Myeloma and Leukemia
Vol/bind21
Udgave nummerSuppl. 1
Antal sider1
ISSN2152-2650
DOI
StatusUdgivet - 2021
BegivenhedThe ninth annual meeting of the Society of Hematologic Oncology - Virtuelt
Varighed: 8. sep. 202111. sep. 2021
Konferencens nummer: 9

Konference

KonferenceThe ninth annual meeting of the Society of Hematologic Oncology
Nummer9
LokationVirtuelt
Periode08/09/202111/09/2021

Citationsformater